In This Article:
San Diego, California--(Newsfile Corp. - February 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of critically important intracellular antioxidants and other therapeutic compounds, today announced that it has entered into a consulting and investor relations agreement effective February 15, 2025 (the "Agreement") with Bull Markets Media GmbH (the "Consultant"), a Germany-based digital stock market news portal.
The services to be provided by the Consultant include analyzing and assessing opportunities to broaden the Company's shareholder base and expanding the Company's contact network within Europe.
Pursuant to the Agreement, the Company has agreed to pay the Consultant a consulting fee of C$60,000, with fifty per cent payable upon signing of the Agreement and the remainder payable on June 1, 2025. The Company has also agreed to grant the Consultant 100,000 stock options pursuant to the Company's stock option plan. Each option enables the Consultant to acquire one common share at a price of $0.64 per share for a term of 3 years. The options will vest in tranches of 25,000 on each of May 15, August 15, November 15, 2025, and February 15, 2026. The Agreement has a term of twelve months and may be renewed at the end of the term annually for up to two additional years.
The Company and the Consultant act at arm's length and the Consultant has no present interest, directly or indirectly, in the Company or its securities. The Agreement and its terms, including the grant of stock options, are subject to acceptance by the TSX Venture Exchange.
The Company is also pleased to announce that the TSXV has issued final acceptance of the Company's IR contract with Triomphe Holdings Ltd. doing business as Capital Analytica (see the Company's news release dated September 27, 2024).
About Thiogenesis
Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company operating through its wholly owned subsidiary based in San Diego, CA. Thiogenesis is developing sulfur-containing prodrugs that act as precursors to previously approved thiol-active compounds, with the potential to treat serious pediatric diseases with unmet medical needs. Prodrugs are drugs that contain previously approved active ingredients and are modified so that they only become active when metabolized. For regulatory purposes prodrugs can use existing third-party safety data in regulatory submissions in the streamlined 505 (b)(2) regulatory pathway in the US, and its equivalent hybrid system in Europe, to proceed into human efficacy trials with regulatory clearance. Prodrugs may enhance the profile of the active ingredient to increase its bioavailability and reduce side effects. Initial target indications include Mitochondrial Encephalopathy Lactic Acidosis and Stroke ("MELAS"), Leigh syndrome, Rett syndrome and pediatric MASH.